Member Info for Denn92

Merchantbanker is not a fool.

I'm guessing most of you are hoping thats a big seller finished selling and the only way is up?

POSTI - That is just nonsense. Sorry you lost so much here, hence the bitterness.

"Never argue with a fool, onlookers may not be able to tell the difference."

I'll leave it at that. If I were to guess, you clearly aren't a lawyer.

JAdam - we aren't in November, just as an FYI. I am not basing my views on the covid share spikes, I'm basing them on today's value.

Mr Investment, I don't have the exact answer for you but perhaps someone may. All I know is the margins on COVID tests are fairly sizeable across the market. I wouldn't expect it to be any different here.

JAdam,

If you are going to slate me for comparing two companies based on sales, which is a fair way to compare.. please don't then compare the increase in the SP in pence... next time when you do that comparison try looking at the MCAP. On that note, I won't say anymore to respond to your ridiculous comments that clearly show a lack of understanding when it comes to company value.

Current market cap is 1/3rd of Novacyts with probably not even 1/20th of sales.

Legin,

I am not struggling with reality, I appreciate the performance of Novacyt has been remarkable, the best COVID stock. I was in it from 150 and got out at 450. What I am comparing is simply the progress and the commercial updates that are having very little impact on Novacyt and if anything a negative one. I'm not sure why people expect news to have a different outcome for ODX.

Merchant,

Thank you for your considered response.

Have you seen Novacyt's sales? How is it going for them?

Announcing £22m per month in sales and the SP has declined. Now call me pessimistic, but ODX will not be announcing anywhere even close to that quantum, probably not even £1m (that's if they do, if they don't the SP will drop on that basis as well). It's a lose lose to be a trader here at this moment in time and if you are an investor (in covid?), then more fool you.

I think it should be worth realising that sentiment has gone from COVID. Is anybody fussed about what may or may not be announced in the presentation, I know I'm not. They could announce they've made £2m in sales in June, will the SP move, absolutely not. Look at Novacyt as a prime example.

Everyone knows news, good or bad appears to be bringing share prices in the covid market down at the moment. It wouldn't surprise me if there is some good news in the presentation but the market will still see that significantly lower than what any sentiment has ever perceived the expectation to be.

Before COVID this stock was at 7p, for a reason. Given it has really not done a great deal since COVID, the multiplication of 5x to the SP is unwarranted.

Think you are right Newboy58- darnit!

:)

:(

Do you feel you knew the quantum of sales, as I certainly didn't - if anything they exceeded my expectations significantly.

How is the market cap for Novacyt £186m after releasing an RNS with c£300m forecast annual sales with growth not slowing down and expansion into the US market occurring...

Am I missing something blatantly obvious here?

Appreciate the help.

TradesIn, need more than actual sales, need incredible actual sales.... Not a few £m.

Novacyt released an RNS yesterday stating sales figures that would give rise to c£300m per annum (and growing in to 2021) specifically relating to COVID related products. They also comment on their expansion in to the US market...

Novacyt market cap is currently £184m.. so sales are double that. The SP since Friday close has DROPPED 3.5%....

You look at a company like ODX with a market cap of £58m with only £100k of sales and no break in for the US or any other market for that matter. Therefore, to be on par with Novacyt, the market cap should remain at £58m and sales be £116m. Ludicrous, but it also shows the COVID market is well and truly dead.

Novacyt released an RNS yesterday stating sales figures that would give rise to c£300m per annum (and growing in to 2021) specifically relating to COVID related products. They also comment on their expansion in to the US market...

Novacyt market cap is currently £184m.. so sales are double that. The SP since Friday close has DROPPED 3.5%....

You look at a company like GDR with a market cap of £34m with only £1m of sales and no break in for the US or any other market for that matter. Therefore, to be on par with Novacyt, the market cap should remain at £34m and sales be £68m. Ludicrous, but it also shows the COVID market is well and truly dead.

... as any good RNS brings a drop in the SP, obviously - trading is lame!

I don't hold here anymore and haven't since the last 52 week high, but good luck to all holders, I know only too well how frustrating it is seeing a share price tumble and not see any real gain for a period of time. This RNS is huge, c£22m sales for June is c£260m annual revenue no? For a company with a market cap under £200m.. This should at least have a 25%+ jump today.

Also the only COVID stock at present with real sale volumes.

You can **** off now then Punter. Be nice not to see your constant **** in here.